Fda Catalyst Medicines

Methodology inspired by publicly taught biotech catalyst frameworks; all text is an original paraphrase.

Defaults

Preflight

Run canonical pre-flight per contracts/preflight.md. Include the X-Agentii-Trace header on every tool call per contracts/x-agentii-trace-header.md — carry the _run_id from your first tool result and name yourself (and your parent, if you were spawned). Confirm ticker resolution via search_companies before catalyst queries.

Triggers

• "When is the PDUFA date for [drug/ticker]?"
• "What AdCom meetings are coming up for [ticker]?"
• "Has [drug]'s sNDA/sBLA label expansion been approved?"
• "Which biosimilars have interchangeability designation, and when does 180-day exclusivity run?"
• "What is [drug]'s Orange Book patent and exclusivity state?"
• "How is [ticker]'s CRL remediation timeline shaping up?"
• "Build a PDUFA/AdCom calendar for my pharma watchlist."
• "Evaluate the approval odds for [drug] ahead of its AdCom."
• "What label expansions are pending for [ticker] this year?"
• "Which medicine decisions land this quarter?"
• "How do biosimilar launches erode the reference product's share?"
• "Which catalysts overlap with [ticker]'s earnings date?"

Production Grounding

• CDER mechanics: NDA/BLA review tracks, PDUFA target dates, priority review, breakthrough designation, accelerated approval, CRL deficiency classes and the remediation reset, AdCom vote patterns.
• Label expansions (sNDA/sBLA) are the commercial catalysts beyond first approval; Orange Book patent and exclusivity state sets the generic or biosimilar entry window.
• Biosimilar timeline note: interchangeability plus 180-day exclusivity for the first interchangeable delays competing entry — and approval is not launch; commercial timing follows exclusivity expiry and patent-settlement terms.
• Holiday-week labeling discipline: comps across holiday-shifted weeks are noisy; every calendar row carries its caveat, and holiday weeks are labeled explicitly.
• Apply AdCom-style scrutiny axes when framing outcome odds; never fabricate dates, votes, or outcomes — annotate coverage gaps instead (per references/knowledge-frameworks.md).

Data Source Priority

1. Structured catalyst data: get_upcoming_pdufa / get_pdufa_decision (pipeline.fda_calendar_event).
2. AdCom and approval history: search_adcom_meetings / get_adcom_meeting; search_fda_approvals / get_fda_approval.
3. Company and filing context: get_company_profile, search_documents, search_sec_filings; briefing docs via list_sources(source_type=adcom_briefing) + read_source_outline/read_source_pages with meeting slugs.
4. Historical grounding: search_investment_cases (event_type=adcom_vote/pdufa_decision/crl/approval), search_by_analogue, search_investment_strategies (sectors=med).
5. Earnings overlap: search_earnings_calendar / list_upcoming_earnings.

Methodology

Retrieval Scope

unstructured_document_search

Retrieval Strategy

1. Resolve ticker(s) via search_companies; note primary drug/application names.
2. Pull active PDUFA events (get_upcoming_pdufa, horizon_days=default); layer AdCom meetings and earnings dates.
3. Per event: decision history (get_pdufa_decision by drug/application), approval record (get_fda_approval), label and Orange Book state.
4. For AdCom events, retrieve briefing documents via list_sources + read_source_outline/read_source_pages using meeting slugs; apply scrutiny axes.
5. Ground the play in knowledge: search_investment_cases / search_by_analogue with med filters; cite /v/ records.